Safety and Immunogenicity of Four-Segmented Rift Valley Fever Virus in the Common Marmoset

Paul Wichgers Schreur (✉ paul.wichgersschreur@wur.nl)

Wageningen Bioveterinary Research <https://orcid.org/0000-0001-9790-2438>

Petra Mooij

Biomedical Primate Research Centre

Gerrit Koopman

Biomedical Primate Research Institute

Babs Verstrepen

BPRC <https://orcid.org/0000-0002-4666-0798>

Zahra Fagrouch

Biomedical Primate Research Centre

Daniella Mortier

Biomedical Primate Research Institute

Nikki van Driel

Biomedical Primate Research Centre

Jet Kant

Wageningen Bioveterinary Research

Sandra van de Water

Wageningen Bioveterinary Research

Willy Bogers

Biomedical Primate Research Institute <https://orcid.org/0000-0002-4563-8513>

Carine Punt

BunyaVax

Lucien van Keulen

Wageningen Bioveterinary Research, Houtribweg 39, 8221 RA Lelystad

Ernst Verschoor

Biomedical Primate Research Centre <https://orcid.org/0000-0003-0912-2074>

Jeroen Kortekaas

Wageningen Bioveterinary Research

Keywords: Rift Valley fever virus, vaccine, four-segmented, nonhuman primate, common marmoset, safety,

Posted Date: December 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1075403/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.
[Read Full License](#)

Version of Record: A version of this preprint was published at npj Vaccines on May 18th, 2022. See the published version at <https://doi.org/10.1038/s41541-022-00476-y>.

Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset

Short title: Safety and efficacy of RVFV-4s in marmosets

Paul J. Wichgers Schreur^{1,2*}, Petra Mooij³, Gerrit Koopman³, Babs E. Verstrepen³, Zahra Fagrouch³, Daniella Mortier³, Nikki van Driel³, Jet Kant¹, Sandra van de Water¹, Willy M. Bogers³, Carine Punt², Lucien van Keulen¹, Ernst J. Verschoor³, Jeroen Kortekaas^{1,4}

¹Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Wageningen University & Research, Lelystad, The Netherlands

²BunyaVax B.V., Lelystad, The Netherlands

³Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands

⁴Laboratory of Virology, Wageningen University & Research, Wageningen, The Netherlands.

*Corresponding author: paul.wichgersschreur@wur.nl

Abstract

Rift Valley fever virus (RVFV) is an emerging mosquito-borne bunyavirus that is highly pathogenic to wild- and domesticated ruminants, camelids and humans. While animals are exclusively infected via mosquito bites, humans can also be infected via contact with tissues or blood released during the slaughtering of RVFV-infected animals. No human vaccine is available and currently commercialized veterinary vaccines do not optimally combine efficacy with safety. We previously reported the development of two novel live-attenuated RVF vaccines, created by splitting the M genome segment and deleting the major virulence determinant NSs. The vaccine candidates, referred to as the veterinary vaccine vRVFV-4s and the human vaccine hRVFV-4s, were shown to induce protective immunity in multiple species after a single vaccination. Anticipating on accidental exposure of humans to the veterinary vaccine, and to evaluate the safety of the hRVFV-4s candidate vaccine for humans, the safety of each vaccine was evaluated in the most susceptible nonhuman primate model, the common marmoset (*Callithrix jacchus*). Marmosets were inoculated with high doses of each vaccine and were monitored for clinical signs as well as for vaccine virus dissemination, shedding and spreading to the environment. To accurately assess the attenuation of both vaccine viruses, separate groups of marmosets were inoculated with the parent wild-type RVFV strains. Both wild-type

strains induced high viremia and disseminated to primary target organs, associated with mild- to severe morbidity, while both vaccines were well tolerated with absence of dissemination and shedding, while inducing potent neutralizing antibody responses. The results of the studies support the unprecedented safety profile of both vaccines for animals and humans.

Keywords: Rift Valley fever virus; vaccine; four-segmented; nonhuman primate; common marmoset; safety;

Introduction

Rift Valley fever virus (RVFV) belongs to the order *Bunyavirales* (genus *Phlebovirus*, family *Phenuiviridae*) and is the causative agent of Rift Valley fever (RVF). The mosquito-borne virus affects wild- and domesticated ruminants, such as sheep, goats, cattle, buffalo, and camelids, manifesting with liver necrosis and haemorrhagic manifestations, with fatal outcomes especially in young animals. Outbreaks are characterized by abortion storms in sheep herds. In endemic areas, epizootics are generally associated with explosive mosquito populations following heavy rains. A wide range of mosquito species have been associated with transmission of the virus, particularly those within the genera *Aedes* and *Culex*^{1,2}. The virus is currently widespread in Africa and is expected to expand its habitat further, stimulated by climate change and globalization³.

In addition to infecting ruminants, RVFV is also infectious to humans. Humans can be exposed to the virus via contact with contaminated tissues or blood released during the slaughtering of RVFV-infected animals, or via mosquito bites. Although humans generally develop a self-limiting febrile illness, a significant fraction develops neurological disorders or haemorrhagic fever⁴, which is often fatal. Furthermore, increasing evidence suggests that RVFV infection during human pregnancies may result in complications⁵⁻⁷. Presently there are no vaccines or therapeutics available to prevent or treat human infections.

The RVFV genome is divided over three RNA segments of negative polarity that are named after their size; small (S), medium (M) and large (L). The L segment encodes the viral RNA-dependent RNA polymerase. The S segment encodes the nucleocapsid that protects the viral RNA from degradation and is involved in transcription and replication, and a non-structural protein named NSs. NSs interferes with host innate immune signalling pathways and is considered the major virulence determinant of the virus⁸. The M segment encodes a polyprotein precursor that is co-translationally cleaved by host proteases into the structural glycoproteins Gn and Gc. Gn is involved in attachment to target cells and Gc is required for fusion of the viral and endosomal membranes. The M segment additionally encodes a small 14-kDa protein, named NSm, which counteract apoptosis⁹, and a large 78-

kDa glycoprotein, named LGp, that comprises the NSm and Gn coding regions, shown to be important for dissemination of the virus in mosquitoes¹⁰⁻¹².

We previously reported the development of a novel live-attenuated RVF vaccine that was constructed by splitting the M genome segment into two M-type segments, one encoding Gn and the accessory proteins NSm and LGp, and one encoding Gc, resulting in a four-segmented RVFV (RVFV-4s)¹³. To optimize the safety profile, the NSs gene was deleted from the S segment. The technology to create four-segmented RVF viruses was subsequently used to create tailor-made vaccines for both animal and human application. The veterinary vaccine, here referred to as “v”RVFV-4s, is based on strain 35/74 and optimally replicates in ruminant cells, whereas the vaccine to be applied in humans, here referred to as “h”RVFV-4s is based on the naturally attenuated Clone 13 isolate^{14,15}.

Both vRVFV-4s and hRVFV-4s were shown to be safe and efficacious in various rodent and ruminant animal models^{13,16-20}, however, safety-data obtained with a more appropriate model for humans was lacking. Demonstration of safety in a nonhuman primate (NHP) model is not only relevant for the candidate human vaccine, but also for the candidate veterinary vaccine, as veterinarians applying this vaccine could be exposed accidentally to the vaccine virus. NHPs, considering their close phylogenetic relationship to humans, are one of the most predictive models with regard to human vaccine safety and efficacy²¹. Historically, rhesus macaques were used for the evaluation of candidate RVF vaccines and therapeutics, despite their relatively low susceptibility to the wild-type virus^{22,23}. More recently, common marmosets (*Callithrix jacchus*) were shown to provide a more convenient model, as these animals develop higher morbidity, more consistent viremia and marked aberrations in hematological and biochemistry values following wild-type RVFV infection compared to macaques^{24,25}.

In this study, we evaluated safety and immunogenicity of a high dose of the vRVFV-4s vaccine candidate and of 3 doses of the hRVFV-4s vaccine candidate in the common marmoset. We specifically assessed body temperatures, virus dissemination and shedding, and induction of neutralizing antibody responses compared to their parent wild-type RVFV strains.

Results

Experimental design

To assess the safety and immunogenicity of both vRVFV-4s and hRVFV-4s in the marmoset model, we conducted two independent experiments (Fig. 1). In experiment 1, eight marmosets were inoculated with a dose of 10^7 TCID₅₀ of vRVFV-4s via a combined intramuscular (IM) and subcutaneous (SC) route. On day 14 and day 28, four inoculated animals were euthanized to collect organ samples. Another 4 marmosets were inoculated with a 10^7 TCID₅₀ dose of parent strain 35/74, and were necropsied on day 14. In experiment 2, three groups of six animals were inoculated with either 10^5 , 10^6 or 10^7 TCID₅₀ of hRVFV-4s via IM route only as the IM route is the anticipated route for human vaccination. In this experiment, a group of identical size was inoculated with 10^7 TCID₅₀ of virulent parent strain 74HB59. At three weeks post inoculation, all animals of experiment 2 were euthanized and the organs were collected. Animals in both experiments were frequently monitored for body weight and clinical signs, besides continuous monitoring of body temperatures. Furthermore, blood samples were regularly collected for haematological, biochemical, virological and immunological analyses. To assess potential virus shedding, oral and rectal swabs were taken in experiment 2.

Figure 1. Schematic representation of the experimental design. Marmosets of experiment 1 were inoculated with vRVFV-4s and in experiment 2 with hRVFV-4s with the indicated dose and route. In both experiments, control animals were inoculated with the wild-type parent strains; for vRVFV-4s this is strain 35/74 and for hRVFV-4s this is 74HB59. Blood samples were taken regularly as indicated, and body temperatures were monitored continuously by an abdominal implanted AniPillV2. Oral and rectal swabs were taken only during experiment 2.

RVFV-4s inoculated animals do not exhibit behaviour changes, clinical signs or weight loss

None of the animals inoculated with vRVFV-4s (experiment 1) or hRVFV-4s (experiment 2) presented abnormal behaviour or manifested with clinical signs or weight loss during the course of the experiment (Fig. 2a, b). One out of four wild-type RVFV 35/74 inoculated animals (experiment 1, animal M12030) showed tremors starting on day 4 post inoculation. These clinical signs worsened on day 15 and the animal was euthanized consequently. This animal additionally presented with substantial weight loss following inoculation. Of note, this animal presented with some (unaccountable) weight loss already prior inoculation. The other three animals of this group did not show clinical signs and were euthanized at the end of the experiment. In experiment 2, approximately 11 days post inoculation (DPI), four out of six control animals inoculated with wild-type strain 74HB59 (M16010, M16017, M16040, and M17011) started to show clinical signs, such as unkempt coats and hunched postures. The general health of animal M16010 and M17011 gradually improved over time, but at 13 and 14 DPI the physical condition of marmosets M16040 and M16017 deteriorated to a lethargic state, reaching a pre-defined humane endpoint. Of note, animal M17058 presented with shallow breathing, unkempt coat and a hunched posture for 2 days starting at day 14 post inoculation. This animal recovered but maintained shallow breathing until the end of the study (day 21). Disease severity was more pronounced in marmosets inoculated with the 74HB59 strain compared to strain 35/74. No behavioural changes, clinical signs or weight loss were observed in any of the vRVFV-4s or hRVFV-4s animals.

Figure 2. RVFV-4s inoculated animals demonstrate no significant weight loss. Body weights relatively to day post inoculation (DPI) 0 measured in experiment 1 (a) and experiment 2 (b). Standard deviations are presented at each time point and spline trendlines were added (Graphpad Prism 9.0). No statistically significant differences were observed between groups.

122

123 **Transient, dose-dependent body temperature increases in RVFV-4s inoculated marmosets**

124 All animals were implanted with an Anipill, a telemetric device to continuously monitor the abdominal body
125 temperatures. Before inoculation, all animals showed a normal circadian pattern, with a body temperature of
126 approximately 39°C during the day versus 36°C during the night. Following inoculation with either vRVFV-4s or
127 hRVFV-4s, a consistent transient elevation of the night-time body temperatures was observed in all animals
128 inoculated with a 10^7 TCID₅₀ dose, starting at DPI 1, and persisting for approximately 24 hrs (Fig. 3). At lower
129 doses (10^6 or 10^5 TCID₅₀, Experiment 2), the transient elevation was less pronounced. Marmosets inoculated
130 with the wild-type virus did not show this early-phase temperature increase but instead had a more pronounced
131 temperature increase at 2-4 DPI that persisted on average for 1.5-2 days (Fig. 3).

Figure 3. Dose dependent early-phase temperature increase following inoculation of marmosets with RVFV-4s. Body temperatures in experiment 1 (a) and experiment 2 (b) were recorded every 15 min using an Anipill telemetric device in the abdominal cavity. Averages and SEM are presented for each group. Area under the curve (AUC) measurements were performed at the indicated days post inoculation (DPI) to assess statistical significant differences between groups of experiment 1 (c) and, groups of experiment 2 (d). Data were analysed by an unpaired T-test (GraphPad Prism 9.0) and statistical significance (p value ≤ 0.05) is indicated with an asterisk (*).

RVFV-4s inoculation resulted in minor changes in haematology and no clinical chemistry changes

Following inoculation with wild-type strain 35/74 in experiment 1, both animals sampled on day 1 post inoculation (M15045 and M15046) showed a minor increase in white blood cell (WBC) and neutrophil counts (Figure 4). No changes were observed at other time points and no changes were observed in lymphocyte and monocyte counts. In the vRVFV-4s inoculated animals all cell numbers remained within the normal range as observed with historic control animals at all time points assessed. In experiment 2, the overall haematology pattern slightly differed compared to experiment 1. The WBC and neutrophil counts at day 1 post inoculation (3 out of 3 animals assessed) were elevated compared to day 0 following hRVFV-4s inoculation. The animals inoculated with 10^7 TCID₅₀ had higher WBC and neutrophil counts compared to the groups inoculated with lower doses, suggesting a dose response. No increases in WBC and neutrophil counts were observed in animals inoculated with the corresponding wild-type strain. Furthermore, no differences were observed in lymphocyte or monocyte counts following inoculation of either wild-type strain 74HB59 or hRVFV-4s.

As RVFV is a hepatotropic virus we also assessed the levels of systemic liver enzymes and renal function parameters in both experiments. Following inoculation with the wild-type strains (experiment 1 and 2) no major changes were observed, except for animal M12030 which presented with increased liver enzymes and renal function parameters in plasma (Fig. 4). No changes in blood chemistry of the vRVFV-4s or hRVFV-4s inoculated animals were observed.

Figure 4. Short term neutrophilia following hRVFV-4s inoculation and no changes in blood chemistry following either vRVFV-4s or hRVFV-4s inoculation. WBC, neutrophil, lymphocyte and monocyte counts measured in blood collected from animals from experiment 1 (a) and animals from experiment 2 (b) at the indicated time points. Creatinine, ALAT, alkaline phosphatase (ALP) and urea levels in plasma measured in animals from experiment 1 (c) and animals from experiment 2 (d), at the indicated time points. In the first week post inoculation, blood samples were obtained every other day of an individual animal (Fig 1). Averages and SEM are presented for each group. No statistical analysis could be performed due to the low number of measurements per time point.

Absence of viremia in RVFV-4s inoculated animals

One of the key safety parameters for live-attenuated vaccines is absent or limited vaccine virus viremia in the vaccinated individual, thereby reducing or even preventing unwanted introduction of the vaccine in the environment, either through shedding or via vectors, such as mosquitoes. To investigate if RVFV-4s induces viremia in marmosets, plasma samples were collected at regular timepoints after inoculation and tested for the presence of viral RNA and infectious virus. In both experiments, high levels of viral RNA and infectious virus were detected in plasma of marmosets inoculated with the parent viruses at 2-4 days post inoculation. Both viral RNA and infectious virus gradually decreased to undetectable levels at 11 and 7 DPI, respectively (Fig 5a-d). Peak viremia in animals inoculated with wild-type virus coincided with increases in abdominal body temperatures (Fig. 3). In the vRVFV-4s and hRVFV-4s inoculated animals viral RNA was detected at DPI 1 and gradually declined to a level below the detection limit around DPI 5. The total genome copy numbers detected at this time point ($<10^7/\text{ml}$) were approximately three logs lower than the total number of genome copies present in the inoculum ($>10^{10}/\text{ml}$). No increases in viral RNA levels were detected in these animals, suggesting that RVFV-4s inoculation does not result in vaccine virus viremia. This is supported by the lack of detectable infectious vaccine virus in blood collected from RVFV-4s inoculated animals (Fig 5c and d).

Figure 5. No infectious virus recovered from plasma of RVFV-4s inoculated marmosets. Plasma samples were assessed for the presence of viral RNA by RT-qPCR (a, b) and for infectious virus by virus isolation (c, d). Samples that tested negative are depicted at the detection limit of the PCR (2.6 log₁₀ RNA copies/ml) or virus isolation (1.95 log₁₀ TCID₅₀/ml). In the first week post inoculation, the animals were allotted to one of two sampling groups. Animals in each group were bled every other day to minimize withdrawal volumes (see Fig 1).

Absence of RVFV-4s dissemination to RVFV target organs

To determine if RVFV-4s vaccine viruses disseminated in the inoculated marmosets, we assessed a broad range of organs for the presence of viral RNA. Of note, most of the organs were obtained at necropsy at 2, 3 or 4 weeks post inoculation, at which time viremia of the parent viruses had subsided. Nevertheless, in animals inoculated with the parent viruses (experiments 1 & 2) viral RNA was detected in liver, brain, spleen, kidney, lymph node, heart and adrenal gland samples (Figs. 6a and b). Furthermore, a few bone marrow, retina and ovary samples were positive for viral RNA, albeit at a very low level. Notably, from the animals that were euthanized upon reaching a humane

end-point, a very high PCR signal was obtained from a kidney sample of animal M12030 (experiment 1) and a moderate signal for brain samples of animals M16017 and M16040 (experiment 2). Histopathological and immunohistochemical examination revealed an extensive tubulo-interstitial nephritis in animal M12030 with strong RVFV immunolabelling of the renal tubular epithelium and proteinaceous/ cellular casts within the tubuli. (Supplementary Fig.1, panel A and B). Animals M16017 and M16040 showed a multifocal meningo-encephalitis with immunostaining of neurons and neuronal processes throughout the brain (Supplementary Fig 1, panel C and D).

In the vRVFV-4s inoculated animals no viral RNA was detected in liver, spleen, kidney, heart and adrenal gland samples, but viral RNA was detected in various lymph node samples and occasionally in spleen samples. Remarkably, the overall number of RVFV-4s RNA positive lymph node samples was higher in experiment 1 compared to experiment 2.

Absence of hRVFV-4s dissemination to the environment

To investigate vaccine virus dissemination to the environment, rectal and oral swabs were obtained at various time point from all animals that were part of experiment 2 (Fig. 1). No swab samples were collected during experiment 1. PCR analysis revealed low levels of viral RNA in both oral and rectal swab samples collected from animals inoculated with the wild-type viruses, whereas no viral RNA was detected in any sample collected from hRVFV-4s inoculated animals (Fig. 6c and d). These results suggest that hRVFV-4s does not disseminate to the environment.

Figure 6. RVFV-4s does not disseminate to RVFV target organs, while the virus is most likely carried by phagocytes to lymphoid organs. Organ suspensions of marmosets from experiment 1 (a) and experiment 2 (b) as well as rectal (c) and oral swabs (d) of animals from experiment 2 were assessed for the presence of viral RNA by RT-qPCR. The x-axes cross the y-axes at the limit of detection.

Induction of a robust immune response

As neutralizing antibodies are the only known correlate of protection for RVFV, we assessed those responses in both experiments. Starting from DPI 7, neutralizing antibodies were detected in both vRVFV-4s and hRVFV-4s inoculated animals, and neutralizing antibody levels increased up to 3 weeks post inoculation (Fig. 7). In experiment 2, in which several RVFV-4s doses were assessed, lower levels of neutralizing antibodies were observed in animals inoculated with 10^5 TCID₅₀, relative to the higher dose groups. No differences were observed between animals vaccinated with 10^6 and 10^7 TCID₅₀. As expected, all parent virus-inoculated animals developed high levels of neutralizing antibodies. Remarkably, the overall levels of neutralizing antibodies of the parent virus-inoculated animals were only slightly higher compared to those detected in the vRVFV-4s and hRVFV-4s high-dose groups.

Figure 7. RVFV-4s inoculation results in the induction of a robust neutralizing antibody response in marmosets. Plasma samples of experiment 1 (a) and experiment 2 (b) were assessed for the presence of RVFV-specific neutralization antibodies by VNT assay. Violin plots are presented with x-axes crossing the y-axes at the limit of detection.

Discussion

In earlier work, we have demonstrated that the vRVFV-4s vaccine candidate does not disseminate in inoculated ruminants and is not shed from these animals to the environment, while inducing protective immune responses after a single vaccination¹⁶. Anticipating on accidental exposure of humans to this veterinary vaccine, we evaluated its safety in the most susceptible NHP model, the common marmoset. In a similar animal model, we evaluated the safety of the hRVFV-4s candidate human vaccine, in preparation of a first-in-human clinical trial.

For live-attenuated vaccines it is of utmost importance to demonstrate the absence of virulence and inability to spread to the environment. The absence of viremia in RVFV-4s inoculated marmosets highlights that the risk of spread of the vaccine virus to mosquito vectors and subsequent spread to naive hosts is negligible. This is in agreement with our previous observation of absence of viremia in ruminants¹⁶. Furthermore, no virus was detected in the swab samples, as part of the sample panel of experiment 2 (hRVFV-4s). Of note, the levels of viral RNA in swabs were low for the wild-type virus, in line with the inability of RVFV to spread directly from animal to animal without involvement of mosquito vectors²⁶.

While no infectious vaccine virus could be recovered from inoculated marmosets, viral RNA was detectable during the first days after inoculation in plasma samples and in lymphoid organs at the time of necropsy. It is important to realize that about 10^{10} genome copies were administered per individual animal (1 TCID₅₀ was previously shown to be equivalent to about 1000 genome copies¹⁶). Taking into account the small size of a marmoset, 350-400 grams with about 35 ml total blood volume, it is not surprising to detect viral RNA in the circulation early after inoculation. The decline of viral RNA levels in plasma samples at 2 DPI contrasts the exponentially increased RNA levels detected in marmosets inoculated with wild-type virus at 2 DPI. These observations suggest limited, or even absent replication of RVFV-4s *in vivo*. The presence of vaccine virus RNA in lymphoid organs at the time of necropsy can be explained by phagocytosis of vaccine virus, genomic RNA and/or phagocytosis of infected cells by migrating cells (macrophages, dendritic cells, neutrophils). Notably, the number of lymphoid organs positive for viral RNA in experiment 1 was higher compared to experiment 2. The different inoculation routes (combined IM/SC versus IM) or the different genetic lineages of the vaccine strains used in the independent experiments may be a factor explaining this finding²⁷.

Whereas no untoward effects or inoculation site reactions were noted in RVFV-4s inoculated animals, a dose-dependent body temperature increase was observed consistently in these animals at 24 hrs post inoculation. Importantly, in both experiments, the expected temperature increase in animals inoculated with wildtype virus followed a different pattern and became apparent at 2-3 DPI, which correlated with peak viremia. Most likely, the vaccine viruses were efficiently detected by the marmoset's innate immune system and triggered innate immune

responses with associated pyrexia. It is unlikely that other components besides the virus, like media- or cell components, induced these pyrogenic reactions, since the inocula containing the wild-type virus was prepared using the same cells and culture medium. Considering that the NSs protein, which is only present in the parent viruses, is known to efficiently counteract early innate immune responses⁸, we hypothesize that NSs delays the induction of an innate immune response in marmosets inoculated with wild-type RVFV. It is plausible that also other live-attenuated RVFV candidate vaccines lacking NSs induce a short-lived pyrexia, however, such responses may not have been noted in earlier studies as body temperatures were not measured continuously²⁸, as was done in the present study. Overall, the dose-dependent pyrexia could be considered a mild side effect of the vaccines but also suggests that the vaccines induce potent innate immune responses, likely supporting subsequent adaptive responses.

As part of the safety analysis, we also assessed blood cell counts in both experiments. In general, the overall results with respect to blood cell counts of experiment 1 and experiment 2 were similar, although we observed one striking difference. In experiment 1, increases in total WBC and neutrophil levels were observed in wild-type 35/74 inoculated animals whereas no such changes were observed in vRVFV-4s inoculated animals, while in experiment 2, no increases in WBC and neutrophil levels were observed in marmosets inoculated with the wild-type virus, whereas dose-dependent increases were observed in hRVFV-4s inoculated animals. Remarkably, increased neutrophil levels were detected on only one day. We do not have a clear explanation for the differences in neutrophil counts between the experiments, but it might be related to the differences in genetic background of the vaccines and wild-type viruses²⁷. Nevertheless, the data underscore that the hRVFV-4s vaccine is recognized efficiently by the marmoset's innate immune system. Whether memory cellular immune responses also differ after inoculation with the different vaccines awaits further study.

Altogether, the present work emphasises that both vRVFV-4s and hRVFV-4s have a high safety profile in the marmoset model and that both vaccine viruses induce significant immune responses following vaccination, supporting further development of both vaccines for animal and human vaccination.

Materials and methods

Ethical approval

The study was reviewed and approved by the Dutch “Centrale Commissie Dierproeven” (AVD5020020174224) according to Dutch law, article 10a of the “Wet op de Dierproeven”. The specific experiments were approved by BPRC’s Animal Welfare Body (IvD).

Animals and housing

The experiments were carried out with adult common marmosets (*Callithrix jacchus*) of >350 gram. In experiment 1, 12 female animals were enrolled whereas in experiment 2, 16 male and 8 female animals were used. Animals were identified by a coloured label on a chain and an implanted microchip. The animals underwent a full physical examination, including faecal screening for pathogens and clinical chemistry and haematology evaluation before enrolment into the study. Only healthy individuals with normal clinical chemistry and haematology values were selected. Animals were housed in pairs in hBSL-3 facilities during the study period. The animals were offered a daily diet which was optimized for marmosets at the BPRC. Enrichment was offered daily, and drinking water was available *ad libitum*.

Cells and Viruses

Culture media and supplements were obtained from Gibco unless indicated otherwise. BHK-21 and BSR-T7 cells were maintained in Glasgow minimum essential medium (GMEM) supplemented with 4% tryptose phosphate broth, 1% minimum essential medium nonessential amino acids (MEM NEAA), 1% antibiotic/antimycotic (a/a) and 5% foetal bovine serum (FBS), at 37°C with 5% CO₂. VERO WHO cells were maintained in VP-SFM supplemented with 2% L-glutamine and 0.01% Gentamycin (Sigma). A master seed virus (MSV) batch of vRVFV-4s (previously referred as RVFV-LMMS_{delINS}^{13,16} was prepared by infecting BSR-T7 cells with plaque-purified seed virus, cultured in complete medium (GMEM supplemented with 5% FCS [SAFC], 4% TPB, 0.01% Gentamycin and 1% NeAA) at a multiplicity of infection (MOI) of 0.002 as described previously¹⁶. A pre-seed batch of hRVFV-4s was used to amplify the virus in Vero WHO cells. Wild-type recRVFV-35/74 and wild-type recRVFV-74HB59 were produced in BHK-21 cells, respectively BSR-T7 cells²⁹.

Inoculation

Animals of experiment 1 received a combined subcutaneously (SC) (between shoulder blades) and IM (upper left leg) inoculation of 500 µl at each site with a total of 10⁷ TCID₅₀ vRVFV-4s or parent virus. In experiment 2, all

animals received two IM (upper legs) inoculations of 500 µl at each site (left and right leg) with a total of 10^5 , 10^6 or 10^7 TCID₅₀ of hRVFV-4s or 10^7 TCID₅₀ of parent virus RVFV-74HB59.

Blood sampling

Blood samples were collected daily in the first week after inoculation. To avoid exceeding the monthly maximal amount of blood (1% of body weight) to be drawn, half of the animals were bled on days 1, 3 and 5, the other half on days 2, 4 and 6. Additional blood samples were taken as presented in Fig. 1.

General behaviour and clinical signs

The animals were monitored for clinical signs twice per day. Animal caretakers were blinded for which animal received the high, medium or low dose of the vaccine. Because animals that received the wild-type parent viruses had to be kept separate from animals that received the vaccines, the animal caretakers were not blinded for the wild-type groups. Abnormalities were communicated immediately to the principle investigator. When an animal showed signs of disease during the day, an extra observation was scheduled in the evening. The following clinical parameters were monitored: Appetite, stool consistency, general behaviour, fever (measured via a telemetric device), anorexia, dehydration, vomiting, drooling, ataxia, horizontal nystagmus, head-pressing, tremors, shallow breathing, blood in urine, foaming at mouth, seizures, activity/lethargy, hunched posture in combination with ruffled/unkept fur (see appendix 1). These clinical signs were described previously in NHPs which succumbed after exposure to RVFV²⁵.

Body weights and temperatures

Animals were captured in a perspex cylinder and weighed as such. A telemetric device (AnipillV2 telemetry system (BodyCAP, Hérouville Saint Clair, France) was surgically placed in the abdominal cavity at 4 weeks before inoculation. This device measures the body temperature every 15 mins and transfers data to a receiver enabling monitoring of fever development in real-time.

Isolation and cryopreservation of serum and EDTA plasma

To collect blood samples, animals were sedated with Alfaxan (12 mg/kg, IM route). Blood was drawn from the femoral vein in the groin using aseptic techniques using a Vacutainer blood collection system (Becton Dickinson, Vacutainer systems). EDTA tubes with collected blood were centrifuged for 10 min at $1,000 \times g$ followed by collection of plasma. A volume of 125 µl plasma was used for clinical chemistry measurements. The remaining material was

stored at -80°C for virus detection via PCR and for the detection of RVFV antibodies. Upon euthanasia, 2ml EDTA blood and plain blood samples were collected. Serum samples were prepared by centrifugation of clotted blood for 10 min (1,000 - 1,300 x g), serum was stored at -20°C.

Clinical chemistry and hematology

At indicated time points, haematology and clinical chemistry levels were measured. Hematology parameters were measured in replenished EDTA blood with a Sysmex XT-2000iV Automated Hematology Analyzer (Sysmex® Corporation of America). Clinical chemistry parameters were measured in 125 µl EDTA plasma samples with a Cobas Integra 400 plus machine (Roche Diagnostics).

Euthanasia and necropsy

At the end of the study (day 14/15 or 28 in experiment 1, and day 21 in experiment 2) or upon reaching a humane end-point, animals were euthanized by intramuscular injection of an anesthetic dose of Alfaxan/Ketamin (10 mg/kg, IM route) followed by an overdose of barbiturate (Pentobarbital, 70-100 mg/kg) injected into a vein in the groin. Complete necropsy was performed on all euthanized animals. Tissues were examined for gross pathology, frozen in liquid nitrogen or fixed in 4% buffered formaldehyde for maximally 48 h. Formalin fixed tissues were processed further by dehydration and embedding into paraffin.

Oral and anal swabs

Oral and anal swabs were collected using FLOQSwabs® 516CS01 Ultra Minitip Flocked Swab with 100mm Breakpoint (FLOQSwabs® COPAN Diagnostics Inc). Oral swabs were inserted into the oral cavity and the inside of each cheek was swabbed for a few seconds. The tip of each swab was placed into a 14 ml tube containing 2 ml of transport medium (MEM, 0.5% BSA, 2.5µg/mL Fungizone, 100 U/mL Penicillin, 100µg/mL Streptomycin) and the applicator stick was broken off. Vials with medium and swabs were vortexed for 20 s. Supernatants were centrifuged for 5 min (750 x g) and stored in at least 2 aliquots at -80°C. Anal swabs were placed in transport medium and handled as described above. Possible debris was pelleted by centrifugation (750 x g, 5 min) and supernatants collected and stored in at least 2 aliquots at -80°C.

Detection of viral RNA in plasma and organ suspensions

Frozen organ samples were thawed and subsequently homogenised using IKA Ultra Turrax Tube DT-20 in the presence of CO₂-Independent Medium (CIM) supplemented with 1% a/a to generate 10% organ suspensions. The

suspensions were transferred to 15 ml Falcon tubes and cell debris was removed by centrifugation for 15 min at 4952 x *g*. Organ suspensions (200 µl) or plasma samples (25 µl) obtained in Experiment 1 were added to 50 µl Proteinase K (5 µg/ml, Sigma). Next, 200 µl AL buffer (Qiagen), supplemented with 2 µl polyadenylic acid A (5 mg/ml, Sigma) was added, after which the samples were thoroughly mixed and incubated at 56°C for 15 min. Subsequently, 250 µl 99% ethanol was added and RNA was isolated using the Qiagen RNeasy kit according to the manufacturer's protocol. Organ suspensions (500 µl) or plasma samples (25 µl) obtained in Experiment 2 were added to 2.5 ml NucliSENS easyMAG Lysis Buffer (Biomérieux, Marcy-l'Étoile, France), after which RNA was extracted using the NucliSENS easyMAG (Biomérieux) according to manufacturer's protocol. In both experiments five µl of the RNA was used in a RT-qPCR using the The LightCycler RNA Amplification Kit HybProbe (Roche, Almere, the Netherlands). Primers and probes were purchased from IDT. Forward primer: 5'-AAAGGAACAATGGACTCTGGTCA-3', reverse primer: 5'-CACTTCTTACTACCATGTCTCCAAT-3'; Probe: 5'-6FAM-AAAGCTTTGATATCTCTCAGTGCCCCAA-TMR-3'. Cycling conditions were as follows: 45°C for 30 min, 95°C for 5 min, 45 cycles of 5 s at 95°C and 35 s at 57°C, followed by cooling down to 30°C.

Virus isolation

Virus isolations were performed on PCR-positive plasma samples with a threshold above 10⁵ RNA copies/ml as this has been previously shown to be a cut-off point below which no live virus can be detected¹⁹. Virus isolations were performed by serial dilution in complete CO₂-independent medium (CIM; supplemented with 5% FBS and 1% a/a) supplemented with 3.5 IU/ml heparin. Subsequently, the virus dilutions were incubated with BHK-21 cells. After 1.5 h incubation at RT, the inocula were replaced by fresh medium and after 5 days of culturing the cells at 37°C and 5% CO₂ cytopathic effects were scored.

Virus neutralisation test and ELISA

Serum RVFV neutralising antibodies were measured using a virus neutralization test (VNT)³⁰. Briefly, serial dilutions (50 µl) of heat-inactivated sera (2 h, 56 °C) were incubated with 50 µl of RVFV-4s_eGFP (10^{3.6} TCID₅₀/ml) for 2 h at RT. Subsequently, 20,000 BHK-21 cells (in 50 µl) were added to each well. Plates were incubated for 2 days at 37 °C and 5% CO₂ and scored using an EVOS-FL microscope (Life Technologies). VNT₅₀ titres were calculated using the Spearman–Kärber algorithm. Presence of RVFV nucleoprotein-specific antibodies in sera was determined using the ID Screen® Rift Valley Fever Competition ELISA (ID-Vet, Montpellier, France).

Histology and immunohistochemistry

Paraffin embedded tissues were cut into 4 µm sections, collected on silane-coated glass slides and dried for at least 48 h in a 37°C incubator. After deparaffinization and rehydration in graded alcohols, sections were stained routinely with haematoxylin and eosin (H&E) or immunostained for RVFV antigen. For immunostaining, epitopes were retrieved by autoclaving for 5 minutes at 121°C in pH 6 citrate buffer (Antigen unmasking solution, Vector Laboratories). RVFV Gn-specific monoclonal antibody 4-D4 was used as primary antibody. Specificity of the immunostaining was confirmed with 2 other mAbs directed against the Gc and N protein of RVFV. HRP-conjugated anti-mouse IgG polymer (Invitrogen) was used as secondary antibody and DAB+ as substrate (Dako, Agilent). Sections were counterstained with haematoxylin.

Data availability

All data necessary to interpret, replicate and build upon the methods or findings reported in the article are provided in this article.

Acknowledgements

We thank the animal caretakers for providing assistance in the animal trials. We thank Dr. Schmaljohn (USAMRIID, Fort Detrick, MD) for providing the 4-D4 mAb and Prof. Klaus Conzelmann (Ludwig-Maximilians-Universität, München) for providing the BSR-T7 cells. Experiment 1 was performed within the scope of the Castellum program, funded by the former Ministry of Economic Affairs. Experiment 2 was performed within the LARISSA project and was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).

Competing interests

P.J.W.S. and J.Ko. are inventors of WIPO Patent Application WO/2014/189372 "Bunyaviruses with segmented glycoprotein genes and methods for generating these viruses", owned by BunyaVax B.V. CP is chief executive officer and P.J.W.S. is Chief Scientific Officer/Chief Operations Officer of BunyaVax. The remaining authors declare no competing interests.

Author contributions

P.J.W.S., S.W., and J.Ko. conceived, designed and produced the vaccine. P.J.W.S., J.Ko., L.K., P.M., G.K., B.V., W.B., and E.V. designed the animal experiments. P.J.W.S., P.M., G.K., B.V., Z.F., D.M., N.D., J.Ka., S.W., W.B. and L.K. performed infections, analytical assays, necropsies and histopathology. P.J.W.S., P.M., G.K., B.V., W.B.,

445 C.P., L.k., E.V. and J.Ko. oversaw data analysis. P.J.W.S., P.M., G.K., B.V., W.B., C.P., L.k., E.V., and J.Ko. wrote
 446 the manuscript.

447 References

- 448 1 Moutailler, S., Krida, G., Schaffner, F., Vazeille, M. & Failloux, A. B. Potential vectors of Rift Valley fever
 449 virus in the Mediterranean region. *Vector borne and zoonotic diseases* **8**, 749-753,
 450 doi:10.1089/vbz.2008.0009 (2008).
- 451 2 Turell, M. J. *et al.* Vector competence of selected African mosquito (Diptera: Culicidae) species for Rift
 452 Valley fever virus. *Journal of medical entomology* **45**, 102-108, doi:10.1603/0022-
 453 2585(2008)45[102:vcosam]2.0.co;2 (2008).
- 454 3 Bron, G. M. *et al.* Over 100 Years of Rift Valley Fever: A Patchwork of Data on Pathogen Spread and
 455 Spillover. *Pathogens* **10**, doi:10.3390/pathogens10060708 (2021).
- 456 4 Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. *Viruses* **3**, 493-519,
 457 doi:10.3390/v3050493 (2011).
- 458 5 Baudin, M. *et al.* Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a
 459 cross-sectional study. *Lancet Glob Health* **4**, e864-e871, doi:10.1016/S2214-109X(16)30176-0 (2016).
- 460 6 McMillen, C. M. *et al.* Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct
 461 placental infection. *Sci Adv* **4**, eaau9812, doi:10.1126/sciadv.aau9812 (2018).
- 462 7 Oymans, J., Wichgers Schreur, P. J., van Keulen, L., Kant, J. & Kortekaas, J. Rift Valley fever virus
 463 targets the maternal-foetal interface in ovine and human placentas. *PLoS Negl Trop Dis* **14**, e0007898,
 464 doi:10.1371/journal.pntd.0007898 (2020).
- 465 8 Ly, H. J. & Ikegami, T. Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus
 466 NSs proteins. *Virology journal* **13**, 118, doi:10.1186/s12985-016-0573-8 (2016).
- 467 9 Won, S., Ikegami, T., Peters, C. J. & Makino, S. NSm protein of Rift Valley fever virus suppresses virus-
 468 induced apoptosis. *J Virol* **81**, 13335-13345, doi:10.1128/JVI.01238-07 (2007).
- 469 10 Kading, R. C. *et al.* Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication
 470 in and dissemination from the midgut of *Aedes aegypti* mosquitoes. *PLoS Negl Trop Dis* **8**, e2670,
 471 doi:10.1371/journal.pntd.0002670 (2014).
- 472 11 Weingartl, H. M. *et al.* Rift Valley Fever Virus Incorporates the 78 kDa Glycoprotein into Virions Matured
 473 in Mosquito C6/36 Cells. *PLoS one* **9**, e87385, doi:10.1371/journal.pone.0087385 (2014).
- 474 12 Kreher, F. *et al.* The Rift Valley fever accessory proteins NSm and P78/NSm-GN are distinct determinants
 475 of virus propagation in vertebrate and invertebrate hosts. *Emerging microbes & infections* **3**, e71,
 476 doi:10.1038/emi.2014.71 (2014).
- 477 13 Wichgers Schreur, P. J., Oreshkova, N., Moormann, R. J. & Kortekaas, J. Creation of Rift Valley fever
 478 viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. *Journal of*
 479 *virology* **88**, 10883-10893, doi:10.1128/JVI.00961-14 (2014).
- 480 14 Muller, R. *et al.* Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever
 481 virus, which is altered in the small segment. *Am J Trop Med Hyg* **53**, 405-411,
 482 doi:10.4269/ajtmh.1995.53.405 (1995).
- 483 15 Bouloy, M. *et al.* Genetic evidence for an interferon-antagonistic function of rift valley fever virus
 484 nonstructural protein NSs. *Journal of virology* **75**, 1371-1377, doi:10.1128/JVI.75.3.1371-1377.2001
 485 (2001).
- 486 16 Wichgers Schreur, P. J. *et al.* Safety and efficacy of four-segmented Rift Valley fever virus in young
 487 sheep, goats and cattle. *NPJ Vaccines* **5**, 65, doi:10.1038/s41541-020-00212-4 (2020).
- 488 17 Wichgers Schreur, P. J. *et al.* A single vaccination with four-segmented rift valley fever virus prevents
 489 vertical transmission of the wild-type virus in pregnant ewes. *NPJ Vaccines* **6**, 8, doi:10.1038/s41541-
 490 020-00271-7 (2021).
- 491 18 Wichgers Schreur, P. J. *et al.* Safety and efficacy of four-segmented Rift Valley fever virus in young
 492 sheep, goats and cattle. *NPJ Vaccines* **5**, 65, doi:10.1038/s41541-020-00212-4 (2020).
- 493 19 Wichgers Schreur, P. J., van Keulen, L., Kant, J. & Kortekaas, J. Four-segmented Rift Valley fever virus-
 494 based vaccines can be applied safely in ewes during pregnancy. *Vaccine* **35**, 3123-3128,
 495 doi:10.1016/j.vaccine.2017.04.024 (2017).
- 496 20 Wichgers Schreur, P. J., Kant, J., van Keulen, L., Moormann, R. J. & Kortekaas, J. Four-segmented Rift
 497 Valley fever virus induces sterile immunity in sheep after a single vaccination. *Vaccine* **33**, 1459-1464,
 498 doi:10.1016/j.vaccine.2015.01.077 (2015).
- 499 21 Estes, J. D., Wong, S. W. & Brenchley, J. M. Nonhuman primate models of human viral infections. *Nat*
 500 *Rev Immunol* **18**, 390-404, doi:10.1038/s41577-018-0005-7 (2018).
- 501 22 Morrill, J. C. *et al.* Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response.
 502 *Archives of virology* **110**, 195-212, doi:10.1007/BF01311288 (1990).
- 503 23 Peters, C. J. *et al.* Experimental Rift Valley fever in rhesus macaques. *Archives of virology* **99**, 31-44,
 504 doi:10.1007/BF01311021 (1988).

- 24 Smith, D. R. *et al.* Development of a novel nonhuman primate model for Rift Valley fever. *Journal of virology* **86**, 2109-2120, doi:10.1128/JVI.06190-11 (2012).
- 25 Hartman, A. L. *et al.* Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets. *Journal of virology* **88**, 2235-2245, doi:10.1128/JVI.02341-13 (2014).
- 26 Wichgers Schreur, P. J. *et al.* Co-housing of Rift Valley Fever Virus Infected Lambs with Immunocompetent or Immunosuppressed Lambs Does Not Result in Virus Transmission. *Frontiers in microbiology* **7**, 287, doi:10.3389/fmicb.2016.00287 (2016).
- 27 Ikegami, T. *et al.* Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model. *PLoS One* **12**, e0189250, doi:10.1371/journal.pone.0189250 (2017).
- 28 Smith, D. R. *et al.* Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. *PLoS neglected tropical diseases* **12**, e0006474, doi:10.1371/journal.pntd.0006474 (2018).
- 29 Kortekaas, J. *et al.* Creation of a nonspreading Rift Valley fever virus. *J Virol* **85**, 12622-12630, doi:10.1128/JVI.00841-11 (2011).
- 30 Wichgers Schreur, P. J., Paweska, J. T., Kant, J. & Kortekaas, J. A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test. *Journal of Virological Methods* **248**, 26-30, doi:<https://doi.org/10.1016/j.jviromet.2017.06.001> (2017).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarydatav1.pdf](#)